Abstrait

Stroke prevention with novel oral anticoagulants in patients with nonvalvular atrial fibrillation

Dylan Rajaratnam, Rohan Rajaratnam

Due to the ease of treatment with Novel Oral Anticoagulants (NOACs) when compared to Vitamin K antagonist, Warfarin, this is increasingly becoming the first line anticoagulant in most circumstances. Here we review the major trials of the more readily available NOACs in stroke prevention in the setting of non-valvular atrial fibrillation.